A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
Bernard NorthHemant Mahendrakumar KocherPeter SasieniPublished in: BMC cancer (2019)
Clinical Trials NCT03307148 (11 October 2017).